secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOXYTRAN, INC (BIXT)
CIK:        0001445815
Form:       8-K
Filed at:   2024-07-05T23:59:59+00:00
Accession:  0001493152-24-026269
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioxytran announces Springer book linking hyperbaric oxygenation to BXT-25 drug
-------------------------------------------------------------------------------

- Book by Prof. Mayevsky published by Springer; covers hyperbaric oxygenation and mitochondrial activity.
- BXT-25 is an acellular oxygen carrier (AOC) 5,000x smaller than RBC; aims to replace HBOT.
- MDX Viewer (FDA-approved) measures tissue oxygenation via Brain Metabolic Score (BMS).
- BMS used as biomarker to demonstrate efficacy in upcoming stroke and Alzheimer's trials.
- Company expects coupling BXT-25 with MDX Viewer could shorten clinical trial timelines.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1445815/000149315224026269/0001493152-24-026269-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1445815/000149315224026269/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-026269

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer